infect
human
bk
polyomaviru
small
doublestrand
dna
viru
potenti
result
sever
complic
immunocompromis
patient
describ
vivo
variabl
evolut
bk
polyomaviru
deep
sequenc
data
reveal
highest
genom
evolutionari
rate
describ
doublestrand
dna
virus
ie
substitut
per
nucleotid
site
per
year
high
mutat
rate
virus
allow
escap
immun
surveil
adapt
new
host
combin
mutat
landscap
across
viral
genom
silico
predict
viral
peptid
demonstr
presenc
significantli
code
substitut
within
predict
cognat
hlacbound
viral
peptid
outsid
find
suggest
role
hlac
antivir
immun
perhap
action
killer
cell
immunoglobulinlik
receptor
present
studi
provid
comprehens
view
viral
evolut
immun
escap
dna
viru
littl
known
mechan
evolut
viral
immun
escap
doublestrand
dna
dsdna
virus
studi
evolut
bk
polyomaviru
observ
highest
genom
evolutionari
rate
describ
far
dsdna
viru
rang
rna
virus
usual
evolv
rapidli
furthermor
predict
viral
peptid
determin
immun
escap
suggest
specif
role
hlac
antivir
immun
find
help
futur
advanc
antivir
therapi
provid
step
forward
understand
vivo
viral
evolut
human
bkv
immun
escap
plo
pathogen
http
doi
introduct
viral
evolutionari
rate
vari
strongli
depend
method
use
estim
among
baltimor
group
fastest
evolv
entiti
singlestrand
ss
rna
reversetranscrib
rt
virus
rate
rang
substitut
per
site
per
year
ssi
rate
doublestrand
ds
rna
ssdna
virus
rang
ssi
wherea
dsdna
virus
evolv
slowli
ssi
import
note
estim
dsdna
virus
publish
fact
higher
estim
base
specif
gene
estim
human
papillomaviru
human
adenoviru
hexon
jc
viru
order
ssi
regard
estim
base
dsdna
complet
genom
rang
ssi
find
confirm
virus
fast
evolv
entiti
wherea
human
much
lower
evolutionari
rate
ssi
howev
wellestablish
codiverg
viral
popul
host
suggest
possibl
low
evolutionari
rate
virus
well
exampl
polyomavirus
histor
consid
exampl
humanviru
codiverg
use
marker
human
migrat
pattern
propos
estim
rang
ssi
detail
studi
need
better
understand
dsdna
viru
evolut
vivo
especi
virus
consid
potenti
pathogen
vertebr
major
drive
forc
antivir
immun
high
level
polymorph
human
leukocyt
antigen
hla
gene
despit
recent
report
limit
inform
present
avail
extent
viral
variabl
vivo
especi
whole
viral
genom
level
studi
tackl
variabl
conjunct
hla
genotyp
infect
individu
consequ
viral
escap
mutantsi
virus
produc
mutat
peptid
longer
abl
bind
cognat
hla
moleculeshav
mainli
studi
limit
model
epitop
vitro
system
highli
relev
rna
virus
hiv
hcv
influenza
dengu
see
follow
histor
refer
recent
review
full
bibliographi
subject
see
surpris
rna
virus
adapt
circumv
immun
respons
littl
known
viral
escap
dna
virus
better
understand
epitop
involv
viral
escap
immun
system
could
use
develop
vaccin
specif
treatment
initi
dual
approach
use
bk
viru
bkv
model
bkv
detect
first
time
kb
dsdna
viru
polyomavirida
famili
harbor
six
gene
agnogen
larg
antigen
lta
small
antigen
sta
primari
infect
occur
essenti
childhood
viru
infect
human
popul
viru
remain
persist
throughout
life
primarili
urinari
tract
highlevel
replic
mainli
occur
immunocompromis
host
specif
receiv
investissementsdavenir
addit
support
receiv
strasbourg
high
throughput
next
gener
sequenc
facil
genomax
sb
url
avail
institut
nation
de
la
et
de
la
recherch
inserm
sb
wwwinsermfr
initi
dexcel
idex
fund
univers
strasbourg
unistra
sb
wwwunistrafr
institut
universitair
de
franc
iuf
sb
http
wwwiufrancefr
project
ministri
economi
competit
mineco
spanish
govern
http
wwwidi
minecogob
fgc
project
prometeo
generalitat
valenciana
fgc
wwwgvae
funder
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
modern
immunosuppress
regimen
notabl
postkidney
transplant
bkvassoci
diseas
especi
bkvassoci
nephropathi
affect
transplant
recipi
may
lead
loss
allograft
even
death
specif
prophylact
cur
treatment
earli
diagnosi
well
quick
restor
immun
dampen
immunosuppress
remain
effect
strategi
control
diseas
high
level
variabl
bkv
detect
ng
access
viru
bloodstream
andor
urin
within
transplant
set
hla
allel
donor
recipi
known
provid
uniqu
opportun
studi
viral
evolut
vivo
context
individu
recipi
donor
hla
class
genotyp
retrospect
cohort
samplesthat
underw
solid
organ
n
hematopoiet
cell
transplant
n
harbor
minimum
viral
copiesml
whole
blood
urin
select
quantit
realtim
pcr
show
viral
titer
blood
copiesml
significantli
lower
urin
copiesml
mannwhitney
u
twotail
p
complet
deep
genom
sequenc
sampl
align
bkv
dunlop
refer
strain
genbank
access
number
averag
polymorph
per
sampl
observ
averag
median
coverag
readsposit
tabl
genbank
access
number
see
method
total
amino
acid
posit
agnoprotein
lta
sta
found
polymorph
tabl
agnogen
gene
appar
select
constraint
neigojobori
test
p
other
purifi
select
neigojobori
test
p
fig
see
method
singl
nucleotid
insert
delet
detect
viral
gene
tabl
due
methodolog
limit
short
read
noncod
control
region
includ
analys
occurr
mutat
main
process
gener
genet
variabl
process
genet
drift
gene
flow
select
recombin
respons
shape
genet
structur
variat
viral
popul
present
evid
bkv
strong
purifi
select
even
immunocompromis
host
sever
specif
featur
polyomavirida
eg
limit
size
genom
small
number
gene
overlap
transcript
unit
like
account
outcom
addit
preval
purifi
select
essenti
gene
anticip
virus
requir
complet
viral
cycl
even
immunocompromis
host
mutat
code
region
must
deleteri
high
substitut
rate
impli
accumul
mutat
deleteri
effect
phenomenon
well
known
rna
virus
high
mutat
rate
short
replic
time
similar
result
shown
compar
mutat
fit
effect
evolut
ssrna
ssdna
virus
studi
support
hypothesi
concord
recent
find
evolutionari
rate
gap
small
dsdna
rna
virus
might
wide
previous
thought
recent
studi
lentivirus
reveal
combin
effect
sequenc
satur
purifi
select
explain
timedepend
pattern
rate
variat
purifi
select
act
genet
divers
long
timefram
remov
larg
number
transient
deleteri
mutat
still
present
within
short
timefram
phylogenet
analysi
bkv
complet
genom
avail
genbank
fig
suggest
exist
three
larg
group
genotyp
repres
serotyp
iiiii
iv
subtyp
within
genotyp
limit
differ
short
branch
length
previous
design
genotyp
ii
iii
suggest
exist
one
genotyp
iiiii
two
subtyp
contrast
pronounc
differ
serotyp
ii
iii
similar
phylogenet
classif
observ
analyz
gene
fig
incident
find
indic
current
bkv
classif
revis
due
inconsist
serotyp
genotyp
next
establish
genotyp
sampl
one
refer
strain
genotyp
subtyp
use
phylogenet
analysi
fig
sampl
belong
genotyp
wherea
genotyp
iv
iiiii
less
repres
respect
cluster
patientdepend
independ
sampl
origin
urin
blood
suggest
sampl
like
contain
mixtur
genotyp
mixtur
might
due
multipl
lifelong
infect
replic
virus
recipi
andor
donor
intraand
interpati
evolutionari
rate
estim
bkv
sequenc
sampl
possibl
recombin
mixtur
genotyp
accord
rdp
output
remov
analysi
see
method
estim
intrapati
substitut
rate
bkv
transplant
patient
rang
substitut
per
nucleotid
site
per
year
ssi
differ
substitut
rate
solid
organ
hematopoiet
cell
transplant
recipi
found
ttest
p
estim
interpati
evolutionari
rate
best
substitut
molecular
clock
demograph
model
accord
margin
likelihood
analys
relax
lognorm
uncorrel
clock
bayesian
skylin
demograph
prior
estim
interpati
evolutionari
rate
rang
hdi
maximum
sampl
interv
day
estim
quit
robust
differ
demograph
molecular
clock
model
tabl
evolutionari
rate
base
maximum
likelihood
leastsquar
method
implement
treedat
similar
appli
whole
data
set
ssi
larg
parametr
bootstrap
confid
interv
rang
thu
prevent
consider
reason
estim
howev
dataset
reduc
sequenc
genotyp
n
averag
evolutionari
rate
estim
ci
valu
close
obtain
bayesian
approach
describ
previous
usual
assum
rna
virus
evolv
rate
ssi
dsdna
close
ssi
ssdna
virus
small
genom
evolv
rate
similar
rna
virus
report
previous
illustr
canin
parvoviru
substitut
rate
ssi
case
dsdna
mani
evolutionari
rate
calcul
assumpt
codiverg
viral
human
popul
observ
polyomavirus
recent
substitut
rate
jc
polyomaviru
evalu
ssi
base
result
bayesian
analys
suggest
substitut
rate
bkv
order
ssi
anoth
studi
found
minor
nucleotid
substitut
gene
encod
late
protein
estim
substitut
rate
bkv
order
ssi
fig
experiment
result
show
first
time
use
wholegenom
sequenc
vivo
viral
popul
larg
monocentr
cohort
genom
evolutionari
rate
dsdna
viru
high
rna
virus
import
note
sampl
window
sequenc
may
affect
estim
evolutionari
rate
short
timescal
inflat
recent
studi
shown
estim
evolutionari
rate
lower
broader
sampl
level
longer
timefram
dna
rna
virus
suggest
time
depend
substitut
rate
ubiquit
among
virus
exampl
lentiviru
evolutionari
rate
serial
sampl
year
within
singl
patient
host
order
ssi
reflect
observ
studi
small
dsdna
viru
addit
previou
studi
compar
evolut
ssrna
ssdna
virus
shown
small
genom
kb
evolv
rapidli
regardless
encod
materi
wellknown
correl
genom
size
mutat
rate
also
hold
evolutionari
rate
show
small
dsdna
genom
also
evolv
fast
singlestrand
one
although
bkv
use
host
dna
polymeras
replic
virallyencod
agnoprotein
inhibit
dsdna
break
repair
activ
therebi
potenti
increas
error
rate
bkv
dna
replic
interestingli
cell
tropism
rna
virus
recent
suggest
key
factor
capac
evolv
sinc
virus
replic
epitheli
cell
bkv
character
rapid
replic
higher
substitut
rate
investig
relationship
evolutionari
rate
viru
immunosuppress
drug
regimenh
strength
immun
systemw
analyz
inform
kidney
transplant
recipi
cohort
largest
subgroup
cohort
kidney
transplant
patient
given
either
antithymocyt
globulin
atg
immunolog
highrisk
patient
receptor
immunolog
lowrisk
patient
induct
treatment
tacrolimu
immunolog
highrisk
patient
cyclosporin
immunolog
lowrisk
patient
mainten
therapi
mycophenol
mofetil
steroid
also
part
drug
regimen
highand
lowrisk
patient
evolutionari
analysi
differ
subgroup
show
signific
differ
mutat
load
full
neg
binomi
mix
model
regress
random
effect
intercept
account
repeat
measur
interpati
substitut
rate
rang
overlap
treatment
atg
ssi
ssi
tacrolimu
ssi
cyclosporin
ssi
investig
genet
immun
escap
mechan
bkv
potenti
tcell
epitop
present
hla
class
predict
use
donor
recipi
hla
allel
combin
viral
substitut
found
herein
fig
tabl
see
method
way
determin
put
hla
ligandom
viru
link
individu
cognat
hla
genotyp
interestingli
two
codon
appear
posit
select
correspond
codon
within
predict
epitop
codon
one
highest
level
signific
differ
found
three
predict
hlac
epitop
kffddwdhkvstv
ffddwdhkv
ffddwdhkvstv
codon
locat
within
two
hlaa
predict
epitop
ttnkrrsr
ttnkrrsrssr
also
found
higher
fraction
observ
amino
acid
substitut
within
hlac
epitop
compar
fraction
amino
acid
substitut
outsid
hlac
epitop
onesid
wilcoxon
sign
test
p
opposit
behavior
observ
hlaa
tss
point
repres
valu
previous
publish
genom
evolutionari
rate
note
refer
one
substitut
rate
repres
caption
red
circl
repres
short
time
span
estim
year
blue
squar
repres
longtim
span
estim
year
median
interquartil
rang
indic
case
interand
intrahost
genom
evolutionari
rate
bkv
valu
repres
rang
valu
obtain
studi
fig
differ
contribut
hla
loci
independ
transplant
type
solid
organ
hematopoiet
origin
hla
loci
whether
donor
recipi
assess
threeway
anova
p
therefor
result
suggest
hlac
might
specif
involv
immun
respons
bkv
peptid
select
capac
viral
peptid
possibl
mechanist
explan
find
stem
ampli
document
interact
hlac
natur
killer
nk
cell
express
killer
cell
immunoglobulinlik
receptor
kir
notabl
relev
kir
hlac
interact
describ
viral
infect
involv
nk
cell
immun
respons
bkv
also
report
although
investig
done
confirm
hypothesi
high
evolutionari
rate
rna
virus
allow
escap
immun
pressur
interact
hla
epitop
virus
describ
varieti
rna
virus
hiv
hcv
influenza
dengu
littl
known
immun
escap
dna
virus
studi
herp
simplex
viru
done
improv
vaccin
design
drug
develop
studi
examin
fraction
protein
wholegenom
sequenc
data
work
knowledg
first
predict
epitop
whole
genom
sequenc
studi
vivo
cohort
conjunct
cognat
hla
allel
understand
mechan
involv
immun
escap
dna
viru
result
viral
escap
combin
high
evolutionari
rate
describ
herein
suggest
combin
drug
use
potenti
treatment
bkv
commonli
use
highli
variabl
virus
hiv
hcv
due
variabl
viral
popul
present
singl
patient
observ
studi
present
work
describ
unusu
fast
evolutionari
rate
bkv
vivo
chart
interact
immun
systemthrough
analysi
cognat
hla
alleleswhilst
consid
whole
viral
genom
candid
epitop
offer
blueprint
similar
analys
virus
help
better
ration
antivir
therapi
candid
vaccin
develop
result
suggest
small
dsdna
virus
treat
rna
virus
due
similar
evolut
immun
escap
thu
combin
drug
might
necessari
treatment
bkv
use
fast
evolv
rna
virus
import
note
new
analyt
method
studi
evolutionari
rate
need
better
understand
effect
time
span
improv
comparison
estim
ninetysix
transplant
patient
strasbourg
univers
hospit
franc
high
level
posttranspl
bkv
viruriaa
detect
routin
bkv
test
hospit
clinic
virolog
laboratorywer
enrol
studi
sixtyeight
patient
underw
kidney
transplant
lung
recipi
receiv
doubl
kidneyheart
heartlung
kidneypancrea
transplant
hematopoiet
stem
cell
transplant
total
sampl
includ
urin
patient
whole
blood
patient
includ
urin
sampl
collect
longitudin
patient
patient
enrol
studi
follow
helsinki
guidelin
written
inform
consent
genet
test
obtain
patient
studi
approv
strasbourg
univers
hospit
institut
review
board
rni
urin
whole
blood
sampl
collect
dna
purifi
use
qiaxtractor
instrument
qiagen
hilden
germani
follow
dx
protocol
extract
dna
store
analysi
blood
urin
specimen
assess
use
bk
viru
rgene
quantif
kit
lyon
franc
follow
manufactur
recommend
dna
amplifi
phusion
polymeras
new
england
biolab
usa
use
specif
overlap
primer
nest
pcr
perform
sampl
low
bkv
dna
load
usual
blood
sampl
pcr
product
purifi
use
genejet
dna
purif
kit
thermofish
scientif
waltham
usa
quantifi
qubit
thermofish
scientif
waltham
usa
twentyon
urineblood
pair
sampl
use
sequenc
sanger
method
use
abi
prism
genet
analyz
thermofish
scientif
waltham
usa
bidirect
sequenc
perform
big
dye
termin
kit
thermofish
scientif
waltham
usa
follow
manufactur
recommend
chromatogram
analyz
staden
packag
obtain
consensu
sequenc
sampl
consensus
obtain
compar
result
nextgener
sequenc
assembl
valid
pipelin
urin
blood
sampl
sequenc
ng
pcr
product
sampl
pool
equimolar
amount
librari
construct
barcod
perform
accord
fragment
librari
prepar
protocol
use
ab
librari
builder
system
thermofish
scientif
waltham
usa
librari
quantifi
qubit
thermofish
scientif
waltham
usa
pool
equimolar
amount
templat
bead
prepar
use
solid
ez
bead
system
thermofish
scientif
waltham
usa
templat
bead
subject
sequenc
use
solid
thermofish
scientif
waltham
usa
pairedend
bp
bp
workflow
sequenc
assembl
dunlop
refer
strain
genbank
access
number
use
lifescop
softwar
thermofish
scientif
waltham
usa
comparison
sanger
sequenc
perform
ascertain
correct
assembl
quantifi
variabl
per
sampl
mutat
analyz
seqman
softwar
dnastar
madison
wisconsin
usa
sampl
obtain
list
variant
genom
locat
coverag
qualiti
metric
among
other
establish
cutoff
variant
call
introduc
intern
control
includ
clone
dunlop
refer
strain
pbk
plasmid
atcc
prepar
miniprepar
thermofish
scientif
waltham
usa
b
pcr
amplicon
clone
c
pcr
amplicon
duplic
three
sampl
control
process
use
sequenc
methodolog
establish
rate
sequenc
pcr
error
final
list
variant
select
mean
fisher
exact
onesid
test
compar
evid
obtain
data
everi
potenti
polymorph
estim
error
rate
use
intern
control
base
analysi
bkv
sequenc
variant
found
less
read
remov
analysi
sequenc
align
assembl
dunlop
strain
muscl
implement
mega
version
default
paramet
order
compar
determin
point
mutat
insert
delet
sequenc
variat
better
analysi
code
region
individu
dataset
per
gene
obtain
analysi
synonym
nonsynonym
substitut
neigojobori
test
neutral
perform
mega
version
phylogenet
analys
whole
genom
consensu
sequenc
obtain
sampl
gene
separ
perform
use
mega
version
maximum
likelihood
phylogenet
tree
construct
gener
time
revers
model
gtr
nucleotid
substitut
gamma
distribut
account
rate
heterogen
among
site
model
achiev
lowest
aic
score
similar
analys
perform
bkv
complet
genom
sequenc
collect
genbank
item
found
search
ncbi
nucleotid
databas
bk
polyomaviru
complet
genom
genotyp
popul
differ
sampl
two
approach
perform
first
phylogenet
tree
sampl
one
refer
strain
genotyp
subtyp
obtain
follow
methodolog
explain
previous
determin
genotyp
shortest
branch
distanc
one
refer
second
approach
base
methodolog
propos
luo
colleagu
point
mutat
specif
report
particular
genotyp
describ
estim
evolutionari
rate
bkv
intraand
interpati
analys
perform
upon
multipl
align
consensu
sequenc
test
use
rdp
softwar
potenti
recombin
posit
result
use
least
two
differ
method
implement
rdp
packag
remov
ensu
analys
sampl
show
mixtur
genotyp
also
exclud
sinc
could
interfer
calcul
substitut
rate
estim
intrapati
substitut
rate
use
urin
sampl
twentyf
patient
collect
differ
time
first
posit
sampl
month
calcul
substitut
per
site
per
year
consid
differ
genom
posit
two
differ
time
fix
popul
substitut
revert
refer
base
includ
sinc
possibl
alreadi
present
ancestr
popul
low
frequenc
could
rule
therebi
substitut
appear
de
novo
exhibit
high
proport
popul
fix
substitut
read
includ
approach
methodolog
obtain
conserv
estim
estim
interpati
substitut
rate
consensu
sequenc
first
avail
urin
sampl
patient
known
date
sampl
select
test
rdp
dataset
bkv
sequenc
use
estim
interpati
evolutionari
rate
sequenc
patient
potenti
recombin
maximum
likelihood
phylogenet
tree
obtain
use
phyml
gtr
model
gamma
distribut
invari
site
account
heterogen
among
site
model
determin
appropri
dataset
jmodeltest
tempest
analysi
conduct
detect
correl
genet
diverg
sampl
time
assur
tempor
signal
interpati
dataset
fig
use
bayesian
estim
evolutionari
rate
date
tip
implement
beast
base
previou
result
firth
et
al
consid
three
molecular
clock
model
strict
relax
lognorm
uncorrel
relax
exponenti
uncorrel
two
demograph
model
constant
popul
size
bayesian
skylin
gtr
model
gamma
distribut
invari
site
use
nucleotid
substitut
model
combin
model
select
perform
comput
margin
likelihood
use
path
sampl
step
stone
sampl
analys
lognormalprior
mean
standard
deviat
use
substitut
rate
two
independ
run
million
step
burnin
use
obtain
median
high
probabl
densiti
interv
relev
paramet
model
case
effect
sampl
size
check
tracer
v
avail
http
beastbioedacuk
addit
use
recent
develop
method
volz
frost
use
maximum
likelihood
least
squar
estim
evolutionari
rate
date
base
relax
molecular
clock
method
implement
r
packag
treedat
predict
bkvencod
tcell
epitop
present
hla
allel
hla
highresolut
type
field
done
etabliss
du
sang
grand
est
strasbourg
use
sequencespecif
oligonucleotid
technolog
highresolut
type
data
hlaa
b
c
avail
donor
recipi
pair
use
analysi
use
recipi
viral
popul
case
tabl
netmhc
use
predict
peptid
bind
affin
potenti
hla
class
epitop
occur
bkv
dunlop
refer
protein
hla
class
allel
patient
donor
peptid
elicit
predict
ic
less
nm
consid
epitop
ic
valu
repres
concentr
peptid
displac
standard
peptid
hla
molecul
lower
ic
valu
stronger
affin
peptid
test
hla
molecul
accord
netmhc
paramet
peptid
ic
nm
consid
highaffin
binder
ic
valu
nm
nm
also
test
cutoff
nm
chosen
best
indic
nm
threshold
enough
peptid
predict
bind
nm
possibl
peptid
within
given
protein
predict
bind
furthermor
predict
epitop
test
netchop
predict
whether
epitop
could
produc
human
proteasom
use
default
paramet
strong
bind
peptid
high
likelihood
correctli
cleav
score
predict
higher
default
threshold
includ
analys
calcul
fraction
substitut
amino
acid
within
outsid
hla
epitop
substitut
detect
specif
viral
popul
patient
map
onto
viral
refer
protein
number
substitut
occur
within
outsid
predict
epitop
calcul
protein
hla
allel
patient
donor
respect
count
normal
number
potenti
mutabl
amino
acid
per
categori
ie
within
outsid
epitop
make
compar
across
protein
vari
length
statist
comparison
intern
extern
fraction
perform
onesid
wilcoxon
sign
test
hla
allel
identifi
direct
differ
pvalu
bonferroni
correct
account
multipl
test
tabl
interpati
substitut
rate
summari
interpati
evolutionari
rate
estim
substitutionssiteyear
ssi
bkv
use
differ
molecular
clock
strict
relax
lognorm
uncorrel
relax
exponenti
uncorrel
demographi
constant
size
bayesian
skylin
model
median
highdens
interv
hdi
interv
shown
estim
obtain
two
independ
run
million
gener
burnin
converg
run
ess
check
tracer
pdf
tabl
allel
frequenc
mhc
class
cohort
allel
shown
hlaa
b
c
field
resolut
donor
recipi
pdf
agnoprotein
larg
antigen
lta
small
antigen
sta
predict
peptid
present
hlaa
b
c
bk
polyomaviru
dunlop
refer
strain
list
start
end
amino
acid
protein
length
peptid
peptid
sequenc
hla
allel
present
peptid
shown
ic
peptid
specif
hla
allel
also
includ
pdf
